Human Investing LLC Sells 254 Shares of Abbott Laboratories (NYSE:ABT)

Human Investing LLC cut its position in Abbott Laboratories (NYSE:ABT) by 5.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,455 shares of the healthcare product maker’s stock after selling 254 shares during the quarter. Human Investing LLC’s holdings in Abbott Laboratories were worth $463,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ABT. International Assets Investment Management LLC lifted its position in shares of Abbott Laboratories by 28.4% during the 4th quarter. International Assets Investment Management LLC now owns 12,257 shares of the healthcare product maker’s stock valued at $1,349,000 after acquiring an additional 2,714 shares during the period. Cullen Investment Group LTD. bought a new stake in shares of Abbott Laboratories during the 4th quarter worth $403,000. Keel Point LLC lifted its position in shares of Abbott Laboratories by 11.3% during the 4th quarter. Keel Point LLC now owns 6,791 shares of the healthcare product maker’s stock worth $748,000 after buying an additional 692 shares during the last quarter. Octavia Wealth Advisors LLC lifted its position in shares of Abbott Laboratories by 5.4% during the 4th quarter. Octavia Wealth Advisors LLC now owns 3,520 shares of the healthcare product maker’s stock worth $387,000 after buying an additional 181 shares during the last quarter. Finally, Riverstone Advisors LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter worth $225,000. 75.18% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ABT has been the subject of several research reports. Barclays increased their target price on Abbott Laboratories from $140.00 to $143.00 and gave the company an “overweight” rating in a research report on Monday, July 29th. The Goldman Sachs Group began coverage on Abbott Laboratories in a research report on Thursday, May 30th. They issued a “buy” rating and a $121.00 target price for the company. Evercore ISI decreased their price target on Abbott Laboratories from $125.00 to $120.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Royal Bank of Canada reissued an “outperform” rating and issued a $125.00 price target on shares of Abbott Laboratories in a research note on Tuesday, June 4th. Finally, Edward Jones cut Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $121.00.

Abbott Laboratories Stock Up 0.1 %

Abbott Laboratories stock traded up $0.06 during mid-day trading on Friday, reaching $111.00. The stock had a trading volume of 4,640,889 shares, compared to its average volume of 6,033,337. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.11 and a current ratio of 1.68. Abbott Laboratories has a fifty-two week low of $89.67 and a fifty-two week high of $121.64. The stock’s 50-day simple moving average is $105.40 and its 200-day simple moving average is $108.81. The firm has a market capitalization of $193.10 billion, a PE ratio of 34.61, a price-to-earnings-growth ratio of 2.74 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The company had revenue of $10.38 billion for the quarter, compared to analyst estimates of $10.37 billion. During the same quarter last year, the company earned $1.08 earnings per share. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. On average, sell-side analysts forecast that Abbott Laboratories will post 4.66 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, August 15th. Investors of record on Monday, July 15th were given a $0.55 dividend. The ex-dividend date was Monday, July 15th. This represents a $2.20 annualized dividend and a yield of 1.98%. Abbott Laboratories’s dividend payout ratio is currently 68.54%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.